Background
The value of performing echocardiography in hypertensive patients with electrocardiographic left ventricular hypertrophy (LVH) is uncertain.
Methods
Baseline echo-and electrocardiographic data and cardiovascular events over 4.8 years study treatment were assessed in 922 hypertensive patients in the Losartan Intervention For endpoint reduction in hypertension echocardiography substudy. Patients were grouped according to presence of LVH on both electrocardiogram (eCG) and echocardiogram (n = 515), only on eCG (n = 172), only on echocardiogram (n = 135), or on none tests (n = 100). LVH was diagnosed by Sokolow Lyon and Cornell product criteria by electrocardiography and as LV mass index >116 g/m 2 in men and >104 g/m 2 in women by echocardiography.
results
Patients with LVH on both tests were older, had higher systolic blood pressure and LV mass, lower LV systolic function, and included more patients with aortic regurgitation, albuminuria, and history of ischemic heart disease (all P < 0.05). Incidence of combined myocardial infarction, stroke, or cardiovascular death did not differ between groups. Incidence of hospitalization for heart failure was 5.3 and 2.6 times higher in patients with LVH on both tests compared to patients with LVH on eCG or echocardiogram only (P < 0.01). In Cox regression, LVH on both tests predicted hospitalization for heart failure (hazard ratio 4.29 (95% confidence interval 1.26-14.65), P = 0.020) independent of other covariates including study treatment allocation and history of ischemic heart disease.
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Predicting Heart Failure in Hypertension with LVH on ECG, LVH on echocardiography, and LVH on both tests or on neither test at the baseline visit.
Methods
Patient population. The LIFE trial enrolled hypertensive patients aged 55-80 years with baseline blood pressure 160-200/95-115 mm Hg and LVH on a screening ECG by Cornell voltage duration product or Sokolow-Lyon voltage to evaluate the effect of randomized losartan-or atenolol-based antihypertensive treatment on cardiovascular events over 4.8 years. 18 Patients with myocardial infarction or stroke within 6 months of enrolment, overt heart failure or known LV ejection fraction <40%, were not enrolled. The LIFE echocardiography study was a prospectively planned substudy, which enrolled 960 of the 9,193 participants in the parent trial for annual echocardiographic follow-up. 19 The present post hoc analysis was performed in the 922 patients within the LIFE echocardiography substudy population in whom LVH could be assessed both on ECG and on echocardiogram taken at the baseline study visit. [19] [20] [21] Patients were grouped according to presence of LVH on ECG, LVH on echocardiogram, LVH on both tests, or no LVH on either test. Glomerular filtration rate was estimated by the simplified Modification of Diet in Renal Disease equation. 22 Urinary albumin excretion was assessed by the urinary albumin/creatinine ratio measured in morning spot urine obtained at the clinic baseline visit and was considered increased if the ratio exceeded 3.5 mg/mmol. 23 Echocardiography. Organization, protocol, echocardiographic method, and results of the LIFE echocardiographic substudy have been previously published. 11, 18 All echocardiograms were sent to the Cornell Echocardiography Reading Center for blinded interpretation. For the present analysis, only the baseline echocardiograms were used.
Chamber dimensions were measured following the American Society of Echocardiography recommendations. 24 The LV ejection fraction was calculated by Teichholz method, and values <55% were considered low. 25 LV mass using an autopsy-validated formula. 26 LV mass showed excellent interstudy reliability in a separate study of 183 patients from the Reading Center. 27 LVH by echocardiography was diagnosed if LV mass/ body surface area exceeded the prognostically validated cutoffs 116 g/m 2 in men and 104 g/m 2 in women. 11 Midwall shortening and its relation to circumferential end-systolic stress at the level of the LV minor axis (stress-corrected midwall shortening) were calculated using a previously validated formula. 28, 29 Mitral and aortic regurgitation was assessed by color Doppler using previously described 4-category grading systems. 30, 31 Electrocardiography. Study ECGs were obtained at baseline, after 6 months, and thereafter annually throughout the study. For the present analysis, only the baseline ECG was used. ECG LVH was blindly interpreted at the ECG Core Laboratory at Sahlgrenska University Hospital-Östra in Gothenburg, Sweden and diagnosed by Cornell voltage duration product (QRS duration × (RaVL + SV 3 with 6 mm added in women)) >2,440 mm × msec or by Sokolow-Lyon voltage (SV 1 + RV [5] [6] ) >38 mm. 20, 21 Patients were recruited for the LIFE study based on these ECG LVH criteria on a screening ECG, and 25% of patients did not meet either of these threshold criteria on the baseline study ECG, as a consequence of regression to the mean. In the LIFE study, LV strain was assessed on the baseline ECG at Helsinki University Central Hospital and diagnosed by the presence of a downsloping convex ST segment with an inverted asymmetrical T wave with polarity opposite to the main QRS deflection. 32 Endpoints. The primary composite LIFE study endpoint included cardiovascular death and fatal and nonfatal myocardial infarction and stroke. Hospitalization for heart failure was a prespecified secondary study endpoint. All endpoints were validated by an independent endpoint classification committee. 18 Statistical analyses. Data management and analysis were performed using SPSS 17.0 (SPSS, Chicago, IL) software. Data are presented as mean ± standard deviation for continuous variables and as percentages for categorical variables. Betweengroup comparisons were made by ANOVA with Scheffé's post hoc test for continuous variables and by general linear model with Sidak's post hoc test for categorical variables. Cox regression analysis was used to identify predictors of the primary study endpoint in the total study population. Comparison of the associations of LVH on ECG, on echocardiography, on both, or on neither test with the secondary study endpoint of hospitalization for heart failure was performed by KaplanMeier plot and log rank test. The association of having LVH on both tests with hospitalization for heart failure was tested in a series of Cox regression analyses all including LVH on both tests as a dichotomous covariate and adjusting for age, history of diabetes, history of ischemic heart disease, or baseline LV ejection fraction in individual models. A two-tailed P < 0.05 was considered significant both in univariate and in multivariate analyses.
results
Compared to patients with LVH on ECG only, the group of patient with LVH both on ECG and echocardiography were older, had higher baseline clinic systolic blood pressure, and included more patients with ECG strain pattern on the baseline ECG, albuminuria, or a history of ischemic heart disease ( Table 1) . Patients with LVH on both tests also had lower LV systolic function, whether measured as LV ejection fraction or stress-corrected midwall fractional shortening, and included more patients with low ejection fraction (<55%) and aortic regurgitation on the baseline echocardiogram (all P < 0.05) ( Table 2 ). During 4.8 years of randomized treatment, 103 patients suffered primary study endpoints and 29 were hospitalized for heart failure. In the total study population, baseline LV mass, baseline ECG strain pattern, and baseline SokolowLyon voltage all predicted higher rate of the primary study endpoint (combined cardiovascular mortality, nonfatal myocardial original contributions Predicting Heart Failure in Hypertension 
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Predicting Heart Failure in Hypertension infarction, and nonfatal stroke) in univariate Cox regression analyses, while baseline LV mass, baseline ECG strain pattern, and having LVH on both tests predicted hospitalization for heart failure (all P < 0.01). Using dichotomous definitions of LVH, the incidence of the primary composite endpoint over 4.8-year follow-up was comparable in groups of patients with LVH on ECG (12.2%) and LVH on both tests (12.0%) and did not differ statistically significant from the incidences in groups of patients with LVH on echocardiogram (9.6%) and LVH on neither test at baseline (7.0%, overall P = 0.45). However, incidence of hospitalization for heart failure was markedly higher in patients with LVH on both tests (4.9%) compared to groups of patients with LVH on echocardiography (2.2%), on ECG only (0.6%), and on neither test (0%, P < 0.01) (Figure 1) . In a series of Cox regression analyses, having LVH on both baseline ECG and baseline echocardiogram was associated with 3.6-to 4.9-fold increased risk for hospitalization for heart failure over 4.8 years independent of significant associations of age, history of diabetes mellitus, history of ischemic heart disease, and baseline LV ejection fraction with hospitalization for heart failure in different models ( Table 3) . Of note, baseline ECG strain did not predict hospitalization for heart failure (hazard ratio 1.02 (95% confidence interval 0.38-2.73), P = 0.97) when baseline LVH on both ECG and echocardiogram was included as a categorical variable in the model. In subsequent models, baseline systolic blood pressure, treatment-induced reduction in systolic blood pressure, gender, presence of albuminuria, and study treatment allocation also did not predict hospitalization for heart failure.
discussion
The prognostic importance of LVH measured on a single ECG or echocardiogram is well documented. [3] [4] [5] [6] [7] [8] 10, 14, [32] [33] [34] [35] Assessment of LVH on ECG has been incorporated in standard testing in hypertension guidelines, while use of echocardiography to assess LVH, although highly recommended, is considered an optional test, left to the physicians' preference. 31 From this practice, it might be suggested that diagnosing LVH on ECG and echocardiography provide comparable information on cardiovascular function and risk in hypertension. The present results challenge this understanding by demonstrating that in hypertensive patients with ECG LVH, performing additional echocardiography identifies a subgroup of patients with LVH on both tests, which is characterized by lower LV systolic endocardial and myocardial function, higher prevalence of subclinical LV systolic dysfunction, and subsequent significantly higher risk of hospitalization for heart failure which could not be predicted from clinical factors and ECG LVH alone. The association of LV systolic dysfunction with increased risk for hospitalization for heart failure has also been documented in asymptomatic uncomplicated hypertension. 36 Few previous studies have compared diagnosing LVH on a single echocardiogram to LVH on a single ECG in prediction of risk for future cardiovascular events. However, given the current focus on nonindicated serial cardiac imaging, comparing diagnostic performance combining single tests is highly relevant. In a population-based study of 475 Swedish men aged 70 years, Sundstöm et al. reported that LVH by echocardiography and ECG LVH by Cornell voltage duration product predicted cardiovascular as well as all-cause mortality during 5.2 years of follow-up independent of each other. 34 Moreover, when dividing their population into groups with or without LVH on one or both tests, patients with LVH on both tests had the highest cardiovascular and all-cause mortality. In particular, an additional prognostic value of performing echocardiography was table 3 | Presence of lVh on both ecg and echocardiogram at baseline independently predicted higher rate of hospitalization for heart failure during 4.8 years randomized study treatment in a series of cox regression analyses adjusting for well-known predictors of heart failure in hypertension Results are reported as hazard ratio (95% confidence interval) for variables in the models. ECG, electrocardiogram; LV, left ventricular; LVH, left ventricular hypertrophy; NA, variable not in the model. *P < 0.05. † P < 0.01. 
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Predicting Heart Failure in Hypertension found in hypertensive subjects. 34 Improved prediction of risk for ischemic stroke by combining LVH on echocardiogram and ECG was also reported by Kohsaka et al. from the communitybased Northern Manhattan Stroke Study. 35 In this case-control study, matching 177 patients who had suffered an ischemic stroke and 246 controls, ECG LVH by Sokolow-Lyon, Cornell voltage, and Cornell product as well as LVH by echocardiography were all associated with two-to 2.5-fold increased risk for ischemic stroke independent of other stroke risk factors. However, only ECG LVH by Cornell voltage predicted stroke independent of presence of LVH on echocardiography in their study, and combining LVH on ECG and echocardiography identified a particular high-risk subgroup with a 3.5-fold increased risk for ischemic stroke. 35 Improved prediction of mortality combining LVH by echocardiography and lateral repolarization abnormality on the ECG has also been reported from the Strong Heart Study. 37 In this population-based study in 2,193 North American Indians, Okin et al. demonstrated that having either ST depression of ≥50 µV in leads V5 or V6, a quantitative measure similar to the ECG strain pattern, or LVH on echocardiography predicted twofold increased risk for cardiovascular as well as all-cause mortality. In particular, having both ST depression and LVH on echocardiography identified a subpopulation at even higher risk with 6.3-and 4.6-fold increased risk for cardiovascular and all-cause mortality within 3.1-year follow-up, while individuals without ECG ST depression or LVH on echocardiography had the most favorable prognosis. 37 The present study adds to these reports by demonstrating that hypertensive patients with LVH both on ECG and echocardiogram have lower LV systolic function, as well as significantly increased risk for hospitalization because of congestive heart failure in spite of aggressive systematic antihypertensive treatment. Of note, neither the higher in-treatment systolic blood pressure nor presence of albuminuria predicted incident hospitalization for heart failure in our study population. Hypertension is a major cause of heart failure all over the world and a major public health problem. 33 Development of better diagnostic tools to identify hypertensive patients who retain high risk for heart failure in spite of modern antihypertensive treatment is warranted. Our results suggest that combining LVH assessment on a single ECG and echocardiogram provides a simple tool for additional heart failure risk stratification in asymptomatic high-risk hypertensive patients. Of note, having LVH on both ECG and echocardiogram at study baseline remained an independent predictor of subsequent hospitalization for heart failure even when presence of baseline ECG strain pattern was taken into account, reflecting the close association between ECG strain pattern and echocardiographic LVH and systolic dysfunction. Thus, the present findings add to a previous report from the main LIFE study by Okin et al. demonstrating that presence of ECG strain pattern on the baseline ECG predicted 1.8-and 2.8-fold increased risks of hospitalization for heart failure and death from congestive heart failure, respectively, independent of blood pressure reduction and randomized study drug allocation. 32 In conclusion, hypertension remains a major cause of heart failure all over the world and a major public health problem. Thus, developing better diagnostic tools to identify hypertensive patients who retain high risk for heart failure in spite of modern antihypertensive treatment is warranted. Our results suggest that combining LVH assessment on a single ECG and echocardiogram provides a simple tool for additional heart failure risk stratification in asymptomatic high-risk hypertensive patients which identifies a subgroup of patients with LVH on both tests that are characterized by subclinical LV dysfunction and associated with subsequent higher risk of hospitalization for heart failure.
study limitations
The present analysis has several limitations. First, this is a post hoc analysis within the prospectively conducted LIFE echocardiography substudy database. The LIFE was conducted in hypertensive patients complying with the specific inclusion and exclusion criteria used in the trial to ensure inclusion of high-risk hypertensive patients. Application of the results in less selective groups of hypertensive patients should be done with caution. Second, although all patients had LVH documented on a screening ECG prior to study enrolment, LVH was not found in all patients when ECG was repeated at the baseline randomization visit, mainly as a consequence of regression to the mean phenomenon. However, the group of patients without ECG LVH at baseline may not be representative for hypertensive patient persistently without LVH in serial ECG assessment. Finally, the statistical analysis was limited by the small number of hospitalizations for heart failure which occurred in the study population. The present study did not have statistical power to detect differences in rate of the primary study endpoint between the four groups of patients according to presence or absence of LVH on baseline tests.
